Nanomaterials in Personalized Medicine Market Report 2025

The nanomaterials in personalized medicine market size has grown rapidly in recent years. It will grow from $351.41 billion in 2024 to $392.97 billion in 2025 at a compound annual growth rate (CAGR) of 11.8%. The growth during the historic period is linked to increasing adoption of nanotechnology in drug delivery, rising demand for targeted therapies, growing awareness of the benefits of personalized medicine, expansion of research in biomarker identification, and higher prevalence of chronic diseases.

The nanomaterials in personalized medicine market size is expected to see rapid growth in the next few years. It will grow to $606.39 billion in 2029 at a compound annual growth rate (CAGR) of 11.5%. The growth projected for the forecast period is driven by growing demand for precision medicine, increasing government funding for nanomedicine, expansion of collaborations between biotech and pharmaceutical companies, rising adoption of advanced diagnostic tools, and greater focus on patient-specific treatments. Primary trends during the forecast period include technological advancements in nanoparticle design, developments in nano-based drug formulations, innovations in targeted delivery systems, increased investment in research and development of personalized therapies, and progress in hybrid nanomaterials for medical applications.

The growing demand for personalized medicine is expected to drive the expansion of the nanomaterials in personalized medicine market in the coming years. Personalized medicine involves customizing treatments for individual patients based on their genetic, environmental, and lifestyle factors to enhance treatment outcomes and quality of care. This demand is increasing due to progress in genomic technologies, which allow for accurate identification of genetic variations and the development of targeted therapies for each person. Nanomaterials play a crucial role in personalized medicine by enabling targeted, patient-specific therapies that enhance the effectiveness and safety of treatments. They facilitate precise delivery of drugs, genes, or RNA, minimizing side effects and maximizing therapeutic results. For example, in February 2024, the Personalized Medicine Coalition, a nonprofit organization based in the US, reported that the U.S. Food and Drug Administration approved 26 new personalized medicines in 2023, compared to 12 approvals in 2022. Hence, the rising demand for personalized medicine is fueling growth in the nanomaterials in personalized medicine market.

Leading companies in this market are concentrating on forming strategic partnerships to speed up clinical translation, broaden therapeutic applications, and reduce time-to-market while adapting to changing regulatory requirements. Strategic collaborations involve combining expertise and resources between companies or institutions to accelerate innovation and expand opportunities in personalized medicine. For instance, in May 2025, Acuitas Therapeutics Inc., a biotechnology firm based in Canada, partnered with Integrated DNA Technologies Inc., a US genomics solutions provider, to launch a personalized CRISPR gene-editing therapy delivery using their lipid nanoparticle platform. This therapy treated a single infant with a rare genetic disorder, employing precisely targeted CRISPR payloads, customized dosing, and rapid formulation. This advancement promotes highly individualized treatments, improving therapeutic precision and patient outcomes, while presenting challenges related to scalable manufacturing, stringent regulatory adaptation, and very low-volume production.

In June 2023, Bayer AG, a pharmaceutical and biotechnology company headquartered in Germany, teamed up with Acuitas Therapeutics Inc. to utilize its lipid nanoparticle delivery technology. This collaboration aims to advance Bayer’s in vivo gene editing and protein replacement programs by leveraging Acuitas’ lipid nanoparticle platform to deliver RNA efficiently and selectively, especially to the liver. Acuitas Therapeutics Inc. is a Canadian biotechnology company specializing in lipid nanoparticle delivery systems, which are critical nanomaterials for personalized medicine.

Major players in the nanomaterials in personalized medicine market are Pfizer & Co. Inc., BASF SE, Sanofi S.A., The Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., Abbott Laboratories, Merck KGaA Darmstadt Germany, Evonik Industries AG, Eisai Co. Ltd., TÜV Rheinland AG, OCSiAl S.A., American Elements Inc., Cour Pharmaceuticals Inc., Nanocomposix Inc., NoPo Nanotechnologies Private Limited, Matexcel Biotech Inc., OncoNano Medicine Inc., Molecular Rebar Design Inc., Cello Therapeutics Inc., Apurano Pharmaceuticals GmbH, SGN Nanopharma Inc.

North America was the largest region in the nanomaterials in personalized medicine market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in nanomaterials in personalized medicine report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the nanomaterials in personalized medicine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

Nanomaterials in personalized medicine are highly engineered substances at the nanoscale, designed to interact with biological systems precisely and in a controlled manner. They enable healthcare interventions to be tailored to an individual’s specific genetic, molecular, or physiological characteristics. These nanomaterials enhance therapeutic effectiveness, minimize potential side effects, and improve overall patient outcomes by supporting targeted, controlled, and individualized medical interventions.

The primary types of nanomaterials in personalized medicine include carbon-based nanomaterials, metallic nanoparticles, polymeric nanomaterials, nanostructured materials, and silica nanoparticles. Carbon-based nanomaterials consist of tiny structures primarily made of carbon, such as graphene, carbon nanotubes, and fullerenes. They are available in various formulations, including nanoparticles, nanosuspensions, nanoemulsions, nanocrystals, and nanoformulations for targeted delivery. Technologies used include nanofabrication techniques, bioconjugation methods, surface modification techniques, molecular imaging techniques, and nanotechnology-based screening methods. Applications include drug delivery systems, diagnostics and imaging, therapeutics, regenerative medicine, and vaccines. End users include hospitals, clinics, research laboratories, pharmaceutical companies, biotechnology firms, and academic institutions.

The nanomaterials in personalized medicine market research report is one of a series of new reports that provides nanomaterials in personalized medicine market statistics, including nanomaterials in personalized medicine industry global market size, regional shares, competitors with a nanomaterials in personalized medicine market share, detailed nanomaterials in personalized medicine market segments, market trends and opportunities, and any further data you may need to thrive in the nanomaterials in personalized medicine industry. This nanomaterials in personalized medicine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The nanomaterials in personalized medicine market consists of revenues earned by entities by providing services such as gene and RNA therapy formulation, personalized diagnostic solutions, nanocarrier design and manufacturing, clinical translation support, and custom nanoparticle-based treatment development. The market value includes the value of related goods sold by the service provider or included within the service offering. The nanomaterials in personalized medicine market also includes sales of targeted gene delivery kits, nanoparticle-based diagnostic kits, nanocarrier-enabled vaccine formulations, nano-biosensors, and lab-scale nanofabrication equipment. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.